The effects of the concentration-dependent erythrocyte distribution of TAK-802, a potent acetylcholinesterase inhibitor, on rat pharmacokinetics

Biopharm Drug Dispos. 2016 Nov;37(8):467-478. doi: 10.1002/bdd.2029. Epub 2016 Sep 26.

Abstract

The purpose of this study was to investigate the effect of the concentration-dependent erythrocyte distribution of TAK-802, a potent acetylcholinesterase inhibitor, on rat pharmacokinetics. In an ascending oral dose study, the maximum plasma concentration (Cmax ) of TAK-802 increased in a dose-dependent manner. The time to reach Cmax decreased as the dose increased, whereas the total clearance was independent of the tested dose range. In this intravenous (i.v.) ascending dose study in rats, the apparent distribution volumes at steady state decreased, and the apparent terminal elimination rate constants increased with TAK-802 dose escalation. A marked concentration dependency was observed in an associated in vitro erythrocyte distribution study. The in vitro erythrocyte distribution study results and a relationship analysis between the plasma and blood concentrations of TAK-802 after i.v. dosing revealed that the characteristics of the erythrocyte distribution could be expressed by Langmuir's adsorption formula. The concentration-time profiles of TAK-802 in plasma and whole blood calculated using a nonlinear pharmacokinetic model incorporating the concentration-dependent erythrocyte distribution with optimized parameters fit well to the observed plasma and blood concentration profiles obtained from the i.v. ascending dose study. These results indicate that the concentration-dependent erythrocyte distribution plays a major role in the nonlinear pharmacokinetics of TAK-802 in rats. Copyright © 2016 John Wiley & Sons, Ltd.

Keywords: TAK-802; concentration-dependent; erythrocyte distribution; nonlinear PK.

MeSH terms

  • Animals
  • Cholinesterase Inhibitors / blood*
  • Cholinesterase Inhibitors / pharmacokinetics
  • Cholinesterase Inhibitors / pharmacology
  • Dose-Response Relationship, Drug
  • Erythrocytes / drug effects
  • Erythrocytes / metabolism*
  • Male
  • Protein Binding / drug effects
  • Protein Binding / physiology
  • Pyrroles / blood*
  • Pyrroles / pharmacokinetics
  • Pyrroles / pharmacology
  • Quinolones / blood*
  • Quinolones / pharmacokinetics
  • Quinolones / pharmacology
  • Rats
  • Rats, Sprague-Dawley
  • Tissue Distribution / drug effects
  • Tissue Distribution / physiology

Substances

  • Cholinesterase Inhibitors
  • Pyrroles
  • Quinolones
  • 8-(3-(1-((3-fluorophenyl)methyl)-4-piperidinyl)-1-oxopropyl)-1,2,5,6-tetrahydro-4H-pyrrolo(3,2,1-ij)quinolin-4-one